Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

Highlights ► Cytokines are critical contributors to autoimmune disease, cancer, and other diseases. ► Janus kinases (Jaks) selectively associate with type I and II cytokine receptors. ► Jaks have essential, nonredundant roles in mediating signals via these receptors. ► Ruxolitinib is approved for tr...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in pharmacology 2012-08, Vol.12 (4), p.464-470
Main Authors: Kontzias, Apostolos, Kotlyar, Alexander, Laurence, Arian, Changelian, Paul, O'Shea, John J
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Autoimmune diseases
Autoimmune Diseases - drug therapy
Autoimmune Diseases - immunology
Graft Rejection - drug therapy
Graft Rejection - immunology
Humans
Internal Medicine
Janus Kinases - antagonists & inhibitors
Janus Kinases - immunology
Medical Education
Myeloproliferative Disorders - drug therapy
Myeloproliferative Disorders - immunology
Neoplasms - drug therapy
Neoplasms - immunology
Protein Kinase Inhibitors - pharmacology
Protein Kinase Inhibitors - therapeutic use
Receptors, Cytokine - immunology
Signal Transduction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► Cytokines are critical contributors to autoimmune disease, cancer, and other diseases. ► Janus kinases (Jaks) selectively associate with type I and II cytokine receptors. ► Jaks have essential, nonredundant roles in mediating signals via these receptors. ► Ruxolitinib is approved for treatment of myelofibrosis, a disorder associated with Jak2 mutations. ► Tofacitinib has shown efficacy in trials in rheumatoid arthritis and other autoimmune diseases.
ISSN:1471-4892
1471-4973
DOI:10.1016/j.coph.2012.06.008